Semaglutide injectable syringes recalled nationwide due to sterility assurance concerns
Thrive Health Solutions is recalling 164 pre-filled syringes of Semaglutide 5 mg/mL due to lack of assurance of sterility. The product was distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of an injectable drug with no reported illnesses or injuries. The hazard is theoretical—lack of sterility assurance on an injectable product presents a potential infection risk but has not resulted in confirmed harm.
Plain-English summary
Thrive Health and Wellness, LLC, dba Thrive Health Solutions, is recalling 164 pre-filled syringes of Semaglutide, 5 mg/mL due to lack of assurance of sterility. The affected product was distributed nationwide.
The recalled lots are: C03035J (exp. 7/3/2025), H202959 (exp. 7/6/2025), AB20N110720 (exp. 7/7/2025), AB60N1121 (exp. 7/7/2025), PRX022225-1 (exp. 8/24/2025), and U122024 (exp. 10/26/2025).
Consumers with this product should not use it. If you have received a syringe with one of the affected lot numbers, contact your healthcare provider or pharmacist. The FDA has classified this as a Class II recall.
The recalled product
- Product
- Semaglutide, 5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112
- Manufacturer
- Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)
- Category
- Drug — Injectable / Semaglutide
- Hazard
- lack-of-sterility
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- Lot #: C03035J
- Exp 7/3/2025
- H202959
- exp 7/6/2025
- AB20N110720
- exp 7/7/2025
- AB60N1121
- PRX022225-1
- exp 8/24/2025
- U122024
- exp 10/26/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27